Au cours des deux derniers mois, les équipes du CRCM ont poursuivi une activité scientifique intense, illustrée par de nombreuses publications dans des revues internationales de référence.
Ces travaux témoignent de la diversité des expertises du centre, de la qualité des collaborations engagées et de l’engagement constant des chercheurs à faire progresser la compréhension des mécanismes du cancer et le développement de nouvelles approches thérapeutiques.

Retrouvez ci-dessous l’ensemble des publications scientifiques du CRCM parues sur cette période.

Département OHIO

Équipe Nunès / Devillier

Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer.

Immediate variations in high-dimensional circulating immune cells following pancreatectomy.

Pathophysiological rationale and management of anxio-depressive syndrome among cancer patients.

Équipe Chames

Junctional adhesion molecule-C: A multifunctional mediator of cell adhesion.

Département Translate-it

Équipe Dusetti / Iovanna

Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer.

Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsically disordered protein NUPR1.

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models.

Équipe Benzekry / Ciccolini

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.

Clinical oncology pharmacy: French current situation of pharmaceutical interventions in production units in 2024.

Équipe Mamessier / Bertucci

The plasma nanoDSF denaturation profiles predict the presence of breast cancer.

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

Équipe Pasquier / André

Chemotherapy-free cancer treatment – not for everyone yet.

Pharmacokinetic-Based Dose Adjustment of Selumetinib in 2 Young Children With Neurofibroma.

Département Genome integrity

Équipe Llorente

Tel1 is recruited at chromosomal loop/axis contact sites to modulate meiotic DNA double-strand breaks interference.

Équipe Coulon

Tel1 is recruited at chromosomal loop/axis contact sites to modulate meiotic DNA double-strand breaks interference.

Équipe Lachaud

Alkyne modification of DNA cross-linking antitumor agent SJG-136 to monitor induced lesions in cells by click chemistry.

Département COMET

Équipe Vasseur / Tomasini

The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage.

Équipe Borg / Maina

MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer.

Équipe Charafe / Ginestier

Injury and inflammation promote cancer progression at the anorectal junction.